Skip to main content

Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

AbbVie's VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

Newswire.ca - Thu Feb 8, 7:00AM CST

MONTREAL, Feb. 8, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that VYALEV (foslevodopa/foscarbidopa solution) is now available for the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper- /dyskinesia despite optimized treatment with available combinations of Parkinson's medicinal products.3

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

inside the market
Short sales on the TSX: What bearish investors are betting against
Larry MacDonald